ESMO 2017 | What is the best treatment for RAS wild-type metastatic colorectal cancer?
Alfredo Carrato, MD, PhD, Ramon y Cajal University Hospital, Madrid, Spain, describes interesting trials discussed at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. An interesting trial presented this year investigated FOLFOXIRI plus panitumumab (NCT01358812). It found a high response rate in patients with RAS wild-type metastatic colorectal cancer. Another interesting trial investigated whether to add an EGFR inhibitor after treatment with bevacizumab in RAS wild-type colorectal cancer showed that bevacizumab conferred an improvement in progression free survival.
Get great new content delivered to your inboxSign up